Daisy Arco
Family · Beaumont, TXNPI 1083008320
Payments from drug & device makers
Across 879 payments — averaging $33.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$15K
- AbbVie$3K
- AstraZeneca$2K
- Novo Nordisk$1K
- Bayer$996
- Merck$834
- plus $6K from 25 others
What the payments were for
- Speaking & faculty fees$10,15034%
- Travel & lodging$3,10010%
- Food & beverage$16,24455%
- Education$940%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 146 | $15,239 |
| AbbVie | 169 | $3,168 |
| AstraZeneca | 83 | $2,013 |
| Novo Nordisk | 90 | $1,464 |
| Bayer | 45 | $996 |
| Merck | 43 | $834 |
| GSK | 46 | $802 |
| Pfizer | 33 | $687 |
| Lilly USA, LLC | 39 | $665 |
| Novartis | 38 | $623 |
| Corcept Therapeutics | 21 | $467 |
| Daiichi Sankyo Inc. | 19 | $371 |
| Esperion Therapeutics, Inc. | 16 | $275 |
| Exact Sciences | 11 | $230 |
| Amarin Pharma, Inc. | 11 | $220 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $193 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $192 |
| Astellas Pharma US Inc | 11 | $184 |
| Axsome Therapeutics, Inc. | 8 | $175 |
| Inspire Medical Systems, Inc. | 2 | $172 |
| Dexcom, Inc. | 8 | $147 |
| Boehringer Ingelheim | 5 | $117 |
| Nabriva Therapeutics, PLC | 3 | $63 |
| Lundbeck LLC | 2 | $55 |
| Biohaven Pharmaceuticals, Inc. | 2 | $52 |
| Abbott | 2 | $45 |
| Ironwood Pharmaceuticals, Inc | 2 | $37 |
| Gilead | 2 | $36 |
| Eisai Inc. | 1 | $24 |
| Si-bone, Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,588 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 278 | $183,002 |
| OzempicSemaglutide | 147 | $172,587 |
| FarxigaDapagliflozin Propanediol | 68 | $88,037 |
| OtezlaApremilast | 11 | $68,596 |
| LinzessLinaclotide | 77 | $61,458 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $52,916 |
| VraylarCariprazine Hcl | 22 | $43,659 |
| RybelsusSemaglutide | 17 | $35,170 |
| JardianceEmpagliflozin | 53 | $32,759 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 27 | $28,960 |
| ProliaDenosumab | 16 | $28,003 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $26,333 |
| Praluent PenAlirocumab | 35 | $24,063 |
| TrulicityDulaglutide | 20 | $23,659 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $23,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,464 | $207,757164 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,013 | $111,429103 claims |
| AbbVieLinzess, Vraylar, Synthroid | $3,168 | $106,252111 claims |
| AmgenOtezla, Prolia | $15,239 | $96,59927 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr, Tradjenta | $117 | $87,262120 claims |
| GSKTrelegy Ellipta | $802 | $52,91676 claims |
| Lilly USA, LLCTrulicity | $665 | $23,65920 claims |
| BayerKerendia | $996 | $18,95023 claims |
| PfizerEliquis | $687 | $18,92729 claims |
| Astellas Pharma US IncMyrbetriq | $184 | $15,79923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Beaumont
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.